Data Sheet (Cat.No.T13248)

TargetMol

UK-240455

Chemical Properties



CAS No. : 178908-09-3

Formula: C11H11Cl2N3O5S

Molecular Weight: 368.19

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improvements in motor function in Parkinson's disease models, making it a potential candidate for Parkinson's disease treatment.
Targets(IC50)	NMDAR,iGluR
In vivo	After i.v. administration of UK-240455 to male rats, UK-240455 exhibits a clearance of 12 mL/min/kg and a volume of distribution of 0.4 L/kg. The plasma concentration of UK-240455 shows a decrease with an apparent half-life of 0.4 h. The analysis of urine (0 to 24 h) reveals that 57% of the administered dose is excreted unchanged. Thus, the urine clearance rate of UK-240455 in rats amounts to 7 mL/min/kg. Upon oral administration to male rats, the apparent elimination half-life of UK-240455 from plasma was observed to be 1.6 hours.[1]

Solubility Information

Solubility	DMSO: 12 mg/mL (32.59 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.716 mL	13.5799 mL	27.1599 mL
5 mM	0.5432 mL	2.716 mL	5.432 mL
10 mM	0.2716 mL	1.358 mL	2.716 mL
50 mM	0.0543 mL	0.2716 mL	0.5432 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Webster R, et al. Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man. Xenobiotica. 2003;33(5):541-560.
Capelli AM, et al. UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001;2(12):1737-1739.